Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / AltrixBio, Inc.

AltrixBio, Inc.

Series ALowell, MAPharmaceuticals
Facts
Year of incorporation
unknown
Revenue range (Form D)
Decline to Disclosesec.gov
Rounds on record
3
Disclosed raised
$5.0Msum of rounds with a disclosed amount only
Named investors
0
Financing history
3 rounds
  1. Sep 16, 2025
    Series A · $5.0M (disclosed)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “AltrixBio Raises $5 Million Series A Financing and Appoints David Pass as CEO to Advance Lead Candidate into the Clinic”
  2. Apr 30, 2025
    Form D equity offering · $1.2M (form d sold) · 20 investors
    Fact SEC EDGAR Form D data sets (quarterly) · “AltrixBio, Inc. filed Form D: $1,150,015 sold of $10,000,000, Pharmaceuticals”
  3. Mar 18, 2019
    Form D equity offering · $1.2M (form d sold) · 20 investors
    Fact SEC EDGAR Form D data sets (quarterly) · “AltrixBio, Inc. filed Form D: $1,150,015 sold of $10,000,000, Pharmaceuticals”
Investors on record
0 edges
No named investor yet.
People
1 officers, 3 directors
Timeline
4
  1. Sep 16, 2025
    AltrixBio announced Series A of $5,000,000
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
  2. Jun 16, 2025
    AltrixBio, Inc. filed Form D: $1,150,015 sold of $10,000,000, Pharmaceuticals
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
  3. Jun 13, 2025
    AltrixBio, Inc. filed Form D/A: $6,632,847 sold of $6,632,847, Pharmaceuticals
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
  4. Jun 13, 2025
    AltrixBio, Inc. filed Form D: $1,150,015 sold of $10,000,000, Pharmaceuticals
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
Evidence
34 observations
Every observation on this company